Cytosorbents Corporation (CTSO)
Chart Events
Performance Outlook
| Previous Close | 2.3300 |
| Open | 2.3500 |
| Bid | 2.3200 x 4000 |
| Ask | 2.4100 x 800 |
| Day's Range | 2.3200 - 2.4000 |
| 52 Week Range | 1.0300 - 4.1500 |
| Volume | |
| Avg. Volume | 189,724 |
| Market Cap | 103.417M |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6800 |
| Earnings Date | Mar 06, 2023 - Mar 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CTSO
Related Research
- Cytosorbents CorporationAnalyst Report: Illumina IncIllumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic analysis. The company's products and services are sold to genomic research centers, academic institutions, government and commercial laboratories, and hospitals, as well as to pharmaceutical, biotech, agrigenomics, and consumer genomics businesses. The company's portfolio of products and services are designed to accelerate and simplify genetic analysis. The company also invests in startup companies that are pursuing promising genomic-related opportunities. It has roughly 9,800 full-time employees. ILMN shares are included in the S&P 500 index.RatingFair ValueEconomic Moat4 days agoArgus Research
- PR Newswire
CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received regulatory approval from Health Canada allowing inclusion of Canadian sites into the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) randomized, controlled trial.
- PR Newswire
CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has appointed Irina B. Kulinets, Ph.D., as Senior Vice President of Global Regulatory Affairs. Dr. Kulinets brings more than 30 years of experience in regulatory affairs and clinical research of medical devices, biologics, and combination products in multiple t
- Simply Wall St.
Can Cytosorbents (NASDAQ:CTSO) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
